Literature DB >> 11278653

Characterization of mutant neutrophil elastase in severe congenital neutropenia.

F Q Li1, M Horwitz.   

Abstract

Severe congenital neutropenia is a heritable human disorder characterized by neutropenia and acute myelogenous leukemia. We recently determined that the majority of cases result from de novo or autosomal dominantly inherited heterozygous mutations in ELA2, encoding neutrophil elastase. Neutrophil elastase is a chymotryptic serine protease localized in granules of neutrophils and monocytes and is the major target of inhibition of the serpin alpha(1)-antitrypsin. The mutations causing severe congenital neutropenia consist of amino acid missense substitutions, in-frame deletion, splice donor mutation producing a deletion, splice acceptor mutation causing insertion of novel residues, and protein truncating mutations of the carboxyl terminus resulting from nonsense substitutions and deletions leading to frameshifts. We have expressed 14 mutant forms of neutrophil elastase in vitro and have characterized their biochemical properties. The mutations have variable effects on proteolytic activity, eliminating the possibility that the disease results from haploinsufficiency. There is no evidence that the mutant enzymes are cytotoxic. The mutant enzymes retain vulnerability to inhibition by alpha(1)-antitrypsin, but demonstrate variable avidity for interaction with this serpin. Somewhat surprisingly, the mutant enzymes inhibit the wild type enzyme when both are coexpressed within the same cell, suggesting the potential to interfere with normal subcellular trafficking or post-translational processing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278653     DOI: 10.1074/jbc.M010279200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane.

Authors:  Suparna Nanua; Mark Murakami; Jun Xia; David S Grenda; Jill Woloszynek; Marie Strand; Daniel C Link
Journal:  Blood       Date:  2011-02-01       Impact factor: 22.113

3.  Digenic mutations in severe congenital neutropenia.

Authors:  Manuela Germeshausen; Cornelia Zeidler; Manfred Stuhrmann; Marina Lanciotti; Matthias Ballmaier; Karl Welte
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 4.  Severe congenital neutropenias.

Authors:  Julia Skokowa; David C Dale; Ivo P Touw; Cornelia Zeidler; Karl Welte
Journal:  Nat Rev Dis Primers       Date:  2017-06-08       Impact factor: 52.329

5.  A Truncated Granulocyte Colony-stimulating Factor Receptor (G-CSFR) Inhibits Apoptosis Induced by Neutrophil Elastase G185R Mutant: IMPLICATION FOR UNDERSTANDING CSF3R GENE MUTATIONS IN SEVERE CONGENITAL NEUTROPENIA.

Authors:  Yaling Qiu; Yangyang Zhang; Nan Hu; Fan Dong
Journal:  J Biol Chem       Date:  2017-01-10       Impact factor: 5.157

6.  Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis.

Authors:  David S Grenda; Mark Murakami; Jhuma Ghatak; Jun Xia; Laurence A Boxer; David Dale; Mary C Dinauer; Daniel C Link
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

7.  Inducible expression of a disease-associated ELANE mutation impairs granulocytic differentiation, without eliciting an unfolded protein response.

Authors:  Bhavuk Garg; Hrishikesh M Mehta; Borwyn Wang; Ralph Kamel; Marshall S Horwitz; Seth J Corey
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

Review 8.  Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?

Authors:  Alejandro A Schäffer; Christoph Klein
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-12

9.  LRG-accelerated differentiation defines unique G-CSFR signaling pathways downstream of PU.1 and C/EBPepsilon that modulate neutrophil activation.

Authors:  Jing Ai; Lawrence J Druhan; Melissa G Hunter; Megan J Loveland; Belinda R Avalos
Journal:  J Leukoc Biol       Date:  2008-02-13       Impact factor: 4.962

10.  Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2.

Authors:  Richard E Person; Feng-Qian Li; Zhijun Duan; Kathleen F Benson; Jeremy Wechsler; Helen A Papadaki; George Eliopoulos; Christina Kaufman; Salvatore J Bertolone; Betty Nakamoto; Thalia Papayannopoulou; H Leighton Grimes; Marshall Horwitz
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.